MedTrace Logo

Influence of Lipid Lowering on Impaired Coronary Flow

NCT05368545 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2025-04-03

No results posted yet for this study

Summary

This study assess in patients with stable chest pain and coronary artery disease (CAD) determined by coronary CTA whether cholesterol lowering with regression of coronary adverse plaque characteristics is associated with recovery of impaired flow

Conditions

Interventions

DRUG

High intensity lipid lowering

Two different regimens of drugs with different effects on LDL lowering

Sponsors & Collaborators

  • HeartFlow, Inc.

    collaborator INDUSTRY

  • Aarhus University Hospital

    lead OTHER

Principal Investigators

  • Bjarne Norgaard, MD, PhD · Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-15
Primary Completion
2024-04-17
Completion
2024-04-17

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05368545 on ClinicalTrials.gov